PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
Launched by DANCE BIOPHARM INC. · Oct 10, 2017
Trial Information
Current as of May 21, 2025
Terminated
Keywords
ClinConnect Summary
The PK and PD profile of Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be compared to subcutaneous injection of insulin lispro.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • non-diabetic subjects with asthma, or COPD. Non-smokers or smokers quit at least 6 months prior to enrollment. BMI \<= 35 kg/m2. Fasting blood glucose \<= 125 mg/dL.
- Exclusion Criteria:
- • pulmonary disorder other than asthma or COPD. Upper respiratory within previous 4 weeks. Significant exacerbation of asthma or COPD symptoms. Hospitalization for asthma or COPD within previous 3 months. Clinically significant medical condition. Current medications interfering with glucose metabolism.
About Dance Biopharm Inc.
Dance Biopharm Inc. is an innovative biotechnology company dedicated to transforming the management of diabetes through the development of advanced inhalable insulin therapies. By leveraging proprietary technologies, Dance Biopharm aims to enhance patient outcomes and improve the quality of life for individuals with diabetes. The company is committed to rigorous clinical research and development processes, ensuring its products meet the highest standards of safety and efficacy. With a focus on patient-centric solutions, Dance Biopharm is poised to make a significant impact in the field of diabetes care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cypress, California, United States
Patients applied
Trial Officials
Timothy S Bailey, MD
Principal Investigator
AMCR
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials